Dacetuzumab
Dacetuzumab
Dacetuzumab (pronounced da-se-tu-zu-mab) is a monoclonal antibody designed for the treatment of cancer. It was developed by Genentech, a member of the Roche Group.
Etymology
The name "Dacetuzumab" is derived from the International Nonproprietary Naming (INN) system for pharmaceutical substances. The "-mab" suffix indicates it is a monoclonal antibody, while the prefix "Dacetu-" is a unique identifier.
Mechanism of Action
Dacetuzumab works by targeting the CD40 protein, a co-stimulatory protein found on the surface of many immune cells. By binding to this protein, Dacetuzumab can stimulate an immune response against cancer cells.
Clinical Trials
Dacetuzumab has been studied in several clinical trials, including those for non-Hodgkin lymphoma and multiple myeloma. However, as of 2021, it has not been approved for use by any major regulatory authority.
Related Terms
- Monoclonal antibody
- Cancer
- Genentech
- Roche Group
- International Nonproprietary Names
- CD40
- Immune cells
- Clinical trials
- Non-Hodgkin lymphoma
- Multiple myeloma
External links
- Medical encyclopedia article on Dacetuzumab
- Wikipedia's article - Dacetuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski